• to discuss the supply of quality-assured second-line TB drugs and the pipeline for a new “cocktail” of TB drugs;
  • to assess the current state of the art for rapid detection of drug resistance—and its implication for patient management; and
  • to suggest policies to accelerate improvements in drug-resistant TB treatment and infection control.

Wednesday, May 26

Conference Venue: International Science & Technology Centre (ISTC)
Krasnoproletarskaya ulitsa, 32-34
127473 Moscow, Russia

09:00–09:30 Welcoming Remarks and Overview of Conference Objectives

Dmitry Orlov, Russian Academy of Medical Sciences
Mikhail Perelman, Moscow Medical Academy
Gail Cassell, Eli Lilly and Company

   
09:30–12:30 Roundtable #1: Magnitude of the Burden of Drug Resistant Tuberculosis—Local and Global Perspectives

Co-Chairs: Marina Yakimova, Central TB Research Institute
Jeffrey Drazen, New England Journal of Medicine

   
  Global Status of MDR/XTR Tuberculosis, 30 min

Salmaan Keshavjee, Chair, Green Light Committee (GLC)
Harvard Medical School

  Epidemiology of TB in the Russian Federation, 30 min

Marina Yakimova, Central TB Research Institute

   
  Prevalence of Drug Resistance at the Initiation of Second-Line Drugs in Eight Countries, 30 min

Peter Cegielski, U.S. Centers for Disease Control and Prevention

   
  Profile of MDR/XDR in South Africa Based Upon Laboratory Data, 30 min

Gerrit Coetzee, National Health Laboratory Service, South Africa



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement